Anti-inflammatory effects of fibrates: An overview

Current Medicinal Chemistry

Volumn 16, Issue 6, 2009, Pages 676-684

  Tziomalos, Konstantinos ^a   Athyros, Vasilios G ^b   Karagiannis, Asterios ^b   Mikhailidis, Dimitri P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Adhesion molecules; C reactive protein; Fibrates; Inflammation; Interleukin; Statins

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BEZAFIBRATE; C REACTIVE PROTEIN; CIPROFIBRATE; CLOFIBRATE; COLESEVELAM; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG STRUCTURE; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLOFIBRIC ACID; HUMANS;

EID: 65649118218     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787458416     Document Type: Review

References (134)

1. Ross, R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med., 1999, 340, 115-26.
2. Ridker, P. M.; Cannon, C. P.; Morrow, D.; Rifai, N.; Rose, L. M.; McCabe, C. H.; Pfeffer, M. A.; Braunwald, E. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med., 2005, 352, 20-8.
3. Ridker, P. M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus. J. Am. Coll. Cardiol., 2007, 49, 2129-38.
4. Nissen, S. E.; Tuzcu, E. M.; Schoenhagen, P.; Crowe, T.; Sasiela, W. J.; Tsai, J.; Orazem, J.; Magorien, R. D.; O'Shaughnessy, C.; Ganz, P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med., 2005, 352, 29-38.
5. Paraskevas, K. I.; Mikhailidis, D. P. C-reactive protein (CRP): More than just an innocent bystander? Curr. Med. Res. Opin., 2008, 24, 75-8.
6. Athyros, V. G.; Kakafika, A. I.; Karagiannis, A.; Mikhailidis, D. P. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis, 2008, 200, 1-12.
7. Prasad, K. C-reactive protein (CRP)-lowering agents. Cardiovasc. Drug Rev., 2006, 24, 33-50.
8. Backes, J. M.; Gibson, C. A.; Ruisinger, J. F.; Moriarty, P. M. Fibrates: What have we learned in the past 40 years? Pharmacotherapy, 2007, 27, 412-24.
9. Tsimihodimos, V.; Miltiadous, G.; Daskalopoulou, S. S.; Mikhailidis, D. P.; Elisaf, M. S. Fenofibrate: Metabolic and pleiotropic effects. Curr. Vasc. Pharmacol., 2005, 3, 87-98.
10. Tziomalos, K.; Athyros, V. G. Fenofibrate: A novel formulation (Triglide) in the treatment of lipid disorders: A review. Int. J. Nanomedicine., 2006, 1, 129-47.
11. Frick, M. H.; Elo, O.; Haapa, K.; Heinonen, O. P.; Heinsalmi, P.; Helo, P.; Huttunen, J. K.; Kaitaniemi, P.; Koskinen, P.; Manninen, V.; Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med., 1987, 317, 1237-45.
12. Rubins, H. B.; Robins, S. J.; Collins, D.; Fye, C. L.; Anderson, J. W.; Elam, M. B.; Faas, F. H.; Linares, E.; Schaefer, E. J.; Schectman, G.; Wilt, T. J.; Wittes, J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med., 1999, 341, 410-8.
13. Keech, A.; Simes, R. J.; Barter, P.; Best, J.; Scott, R.; Taskinen, M. R.; Forder, P.; Pillai, A.; Davis, T.; Glasziou, P.; Drury, P.; Kesaniemi, Y. A.; Sullivan, D.; Hunt, D.; Colman, P.; d'Emden, M.; Whiting, M.; Ehnholm, C.; Laakso, M. Effects of long-term feno-fibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet, 2005, 366, 1849-61.
14. Robins, S. J.; Collins, D.; Wittes, J. T.; Papademetriou, V.; Deedwania, P. C.; Schaefer, E. J.; McNamara, J. R.; Kashyap, M. L.; Hershman, J. M.; Wexler, L. F.; Rubins, H. B. Relation of gemfibrozil treatment and lApid levels with major coronary events: VAHIT: a randomized controlled trial. JAMA, 2001, 285, 1585-91.
15. Brown, J. D.; Plutzky, J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation, 2007, 115, 518-33.
16. Krey, G.; Braissant, O.; L'Horset, F.; Kalkhoven, E.; Perroud, M.; Parker, M. G.; Wahli, W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol., 1997, 11, 779-91.
17. Han, S. H.; Quon, M. J.; Koh, K. K. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension, 2005, 46, 1086-92.
18. Fernandez, A. Z. Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis. PPAR. Res., 2008, 2008, 285842.
19. de Winther, M. P.; Kanters, E.; Kraal, G.; Hofker, M. H. Nuclear factor kappaB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 904-14.
20. Delerive, P.; Gervois, P.; Fruchart, J. C.; Staels, B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J. Biol. Chem., 2000, 275, 36703-7.
21. Kleemann, R.; Gervois, P. P.; Verschuren, L.; Staels, B.; Princen, H. M.; Kooistra, T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood, 2003, 101, 545-51.
22. Gervois, P.; Kleemann, R.; Pilon, A.; Percevault, F.; Koenig, W.; Staels, B.; Kooistra, T. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J. Biol. Chem., 2004, 279, 16154-60.
23. Marx, N.; Sukhova, G. K.; Collins, T.; Libby, P.; Plutzky, J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 1999, 99, 3125-31.
24. Mansouri, R. M.; Bauge, E.; Staels, B.; Gervois, P. Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response. Endocrinology, 2008, 149, 3215-23.
25. Athyros, V. G.; Mikhailidis, D. P.; Papageorgiou, A. A.; Didangelos, T. P.; Peletidou, A.; Kleta, D.; Karagiannis, A.; Kakafika, A. I.; Tziomalos, K.; Elisaf, M. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism, 2005, 54, 1065-74.
26. McKenney, J. M.; Farnier, M.; Lo, K. W.; Bays, H. E.; Perevozkaya, I.; Carlson, G.; Davies, M. J.; Mitchel, Y. B.; Gumbiner, B. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol., 2006, 47, 1584-7.
27. Zhu, S.; Su, G.; Meng, Q. H. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin. Chem., 2006, 52, 2036-42.
28. Nigro, J.; Dilley, R. J.; Little, P. J. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis, 2002, 162, 119-29.
29. Inoue, I.; Shino, K.; Noji, S.; Awata, T.; Katayama, S. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys. Res. Commun., 1998, 246, 370-4.
30. Neve, B. P.; Corseaux, D.; Chinetti, G.; Zawadzki, C.; Fruchart, J. C.; Duriez, P.; Staels, B.; Jude, B. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation, 2001, 103, 207-12.
31. Staels, B.; Koenig, W.; Habib, A.; Merval, R.; Lebret, M.; Torra, I. P.; Delerive, P.; Fadel, A.; Chinetti, G.; Fruchart, J. C.; Najib, J.; Maclouf, J.; Tedgui, A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature, 1998, 393, 790-3.
32. Marx, N.; Schonbeck, U.; Lazar, M. A.; Libby, P.; Plutzky, J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res., 1998, 83, 1097-103.
33. Marx, N.; Duez, H.; Fruchart, J. C.; Staels, B. Peroxisome proliferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ. Res., 2004, 94, 1168-78.
34. Marx, N.; Bourcier, T.; Sukhova, G. K.; Libby, P.; Plutzky, J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 546-51.
35. Marx, N.; Sukhova, G.; Murphy, C.; Libby, P.; Plutzky, J. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am. J. Pathol., 1998, 153, 17-23.
36. Gouni-Berthold, I.; Berthold, H. K.; Weber, A. A.; Seul, C.; Vetter, H.; Sachinidis, A. Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth. Exp. Clin. Endocrinol. Diabetes, 2001, 109, 203-9.
37. Calabresi, L.; Gomaraschi, M.; Villa, B.; Omoboni, L.; Dmitrieff, C.; Franceschini, G. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 656-61.
38. Cockerill, G. W.; Rye, K. A.; Gamble, J. R.; Vadas, M. A.; Barter, P. J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1987-94.
39. Florentin, M.; Liberopoulos, E. N.; Wierzbicki, A. S.; Mikhailidis, D. P. Multiple actions of high-density lipoprotein. Curr. Opin. Cardiol., 2008, 23, 370-8.
40. Alipour, A.; van Oostrom, A. J.; Izraeljan, A.; Verseyden, C.; Collins, J. M.; Frayn, K. N.; Plokker, T. W.; Elte, J. W.; Castro, C. M. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 792-7.
41. Hoogerbrugge, N.; Verkerk, A.; Jacobs, M. L.; Postema, P. T.; Jongkind, J. F. Hypertriglyceridemia enhances monocyte binding to endothelial cells in NIDDM. Diabetes Care, 1996, 19, 1122-5.
42. Tsimihodimos, V.; Kostoula, A.; Kakafika, A.; Bairaktari, E.; Tselepis, A. D.; Mikhailidis, D. P.; Elisaf, M. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J. Cardiovasc. Pharmacol. Ther., 2004, 9, 27-33.
43. Ikewaki, K.; Tohyama, J.; Nakata, Y.; Wakikawa, T.; Kido, T.; Mochizuki, S. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study. J. Atheroscler. Thromb., 2004, 11, 278-85.
44. Ye, P.; Li, J. J.; Su, G.; Zhang, C. Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia. Clin. Chim. Acta, 2005, 356, 229-32.
45. Koh, K. K.; Han, S. H.; Quon, M. J.; Yeal, A. J.; Shin, E. K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care, 2005, 28, 1419-24.
46. Potaczek, D. P.; Undas, A.; Celinska-Lowenhoff, M.; Szczeklik, A. Interleukin-6-174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients. Blood Coagul. Fibrinolysis, 2006, 17, 35-8.
47. Potaczek, D. P.; Undas, A.; Celinska-Lowenhoff, M.; Szczeklik, A. The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects. Cardiovasc. Drugs Ther., 2006, 20, 229-32.
48. Undas, A.; Celinska-Lowenhoff, M.; Domagala, T. B.; Iwaniec, T.; Dropinski, J.; Lowenhoff, T.; Szczeklik, A. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb. Haemost., 2005, 94, 193-9.
49. Okopien, B.; Haberka, M.; Madej, A.; Belowski, D.; Labuzek, K.; Krysiak, R.; Zielinski, M.; Basiak, M.; Herman, Z. S. Extralipid effects of micronized fenofibrate in dyslipidemic patients. Pharmacol. Rep., 2006, 58, 729-35.
50. Sebestjen, M.; Keber, I.; Zegura, B.; Simcic, S.; Bozic, M.; Fressart, M. M.; Stegnar, M. Statin and fibrate treatment of combined hyperlipidemia: The effects on some novel risk factors. Thromb. Haemost., 2004, 92, 1129-35.
51. Wang, T. D.; Chen, W. J.; Lin, J. W.; Cheng, C. C.; Chen, M. F.; Lee, Y. T. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: Relations with baseline lipid profiles. Atherosclerosis, 2003, 170, 315-23.
52. Malik, J.; Melenovsky, V.; Wichterle, D.; Haas, T.; Simek, J.; Ceska, R.; Hradec, J. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc. Res., 2001, 52, 290-8.
53. Melenovsky, V.; Malik, J.; Wichterle, D.; Simek, J.; Pisarikova, A.; Skrha, J.; Poledne, R.; Stavek, P.; Ceska, R. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am. Heart J., 2002, 144, E6.
54. Okopien, B.; Krysiak, R.; Kowalski, J.; Madej, A.; Belowski, D.; Zielinski, M.; Herman, Z. S. Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J. Cardiovasc. Pharmacol., 2005, 46, 377-86.
55. Coban, E.; Ozdogan, M.; Yazicioglu, G.; Sari, R. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients. Int. J. Clin. Pract., 2005, 59, 415-8.
56. Okopien, B.; Krysiak, R.; Herman, Z. S. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J. Clin. Endocrinol. Metab, 2006, 91, 1770-8.
57. Rosenson, R. S.; Huskin, A. L.; Wolff, D. A.; Helenowski, I. B.; Rademaker, A. W. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis, 2008, 198, 381-8.
58. Wu, T. J.; Ou, H. Y.; Chou, C. W.; Hsiao, S. H.; Lin, C. Y.; Kao, P. C. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate. Ann. Clin. Lab Sci., 2007, 37, 158-66.
59. Koh, K. K.; Quon, M. J.; Han, S. H.; Chung, W. J.; Ahn, J. Y.; Kim, J. A.; Lee, Y.; Shin, E. K. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hyper-triglyceridemic hypertensive patients. Diabetes Care, 2006, 29, 195-201.
60. Kon, K. K.; Yeal, A. J.; Hwan, H. S.; Kyu, J. D.; Sik, K. H.; Cheon, L. K.; Kyun, S. E.; Sakuma, I. Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis, 2004, 174, 379-83.
61. Fegan, P. G.; Shore, A. C.; Mawson, D.; Tooke, J. E.; MacLeod, K. M. Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. Diabet. Med., 2005, 22, 1670-6.
62. Hogue, J. C.; Lamarche, B.; Tremblay, A. J.; Bergeron, J.; Gagne, C.; Couture, P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism, 2008, 57, 380-6.
63. Kim, C. J. Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients. J. Cardiovasc. Pharmacol., 2006, 47, 758-63.
64. Despres, J. P.; Lemieux, I.; Pascot, A.; Almeras, N.; Dumont, M.; Nadeau, A.; Bergeron, J.; Prud'homme, D. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 702-3.
65. Rizos, E.; Kostoula, A.; Elisaf, M.; Mikhailidis, D. P. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology, 2002, 53, 273-7.
66. Rizos, E.; Bairaktari, E.; Ganotakis, E.; Tsimihodimos, V.; Mikhailidis, D. P.; Elisaf, M. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J. Cardiovasc. Pharmacol. Ther., 2002, 7, 219-26.
67. Jonkers, I. J.; Mohrschladt, M. F.; Westendorp, R. G.; van der, L. A.; Smelt, A. H. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: Reversal with bezafibrate therapy in a randomized controlled trial. Am. J. Med., 2002, 112, 275-80.
68. Tanne, D.; Benderly, M.; Goldbourt, U.; Haim, M.; Tenenbaum, A.; Fisman, E. Z.; Matas, Z.; Adler, Y.; Zimmlichman, R.; Behar, S. C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease. Stroke, 2006, 37, 1720-4.
69. Hongo, M.; Tsutsui, H.; Mawatari, E.; Hidaka, H.; Kumazaki, S.; Yazaki, Y.; Takahashi, M.; Kinoshita, O.; Ikeda, U. Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: A 5-year follow-up study. Circ. J., 2008, 72, 722-8.
70. Ikewaki, K.; Noma, K.; Tohyama, J.; Kido, T.; Mochizuki, S. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia - a nuclear magnetic resonance study. Int. J. Cardiol., 2005, 101, 441-7.
71. Desideri, G.; Croce, G.; Tucci, M.; Passacquale, G.; Broccoletti, S.; Valeri, L.; Santucci, A.; Ferri, C. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: Evidence of different vascular protection by different lipid-lowering treatments. J. Clin. Endocrinol. Metab, 2003, 88, 5341-7.
72. Cortellaro, M.; Cofrancesco, E.; Boschetti, C.; Cortellaro, F.; Mancini, M.; Mariani, M.; Paoletti, R. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment. Thromb. Haemost., 2000, 83, 549-53.
73. Gomez-Gerique, J. A.; Ros, E.; Olivan, J.; Mostaza, J. M.; Vilardell, M.; Pinto, X.; Civeira, F.; Hernandez, A.; da Silva, P. M.; Rodriguez-Botaro, A.; Zambon, D.; Lima, J.; Diaz, C.; Aristegui, R.; Sol, J. M.; Chaves, J.; Hernandez, G. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis, 2002, 162, 245-51.
74. Ridker, P. M.; Rifai, N.; Stampfer, M. J.; Hennekens, C. H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation, 2000, 101, 1767-72.
75. Pradhan, A. D.; Manson, J. E.; Rossouw, J. E.; Siscovick, D. S.; Mouton, C. P.; Rifai, N.; Wallace, R. B.; Jackson, R. D.; Pettinger, M. B.; Ridker, P. M. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the Women's Health Initiative observational study. JAMA, 2002, 288, 980-7.
76. Ryan, K. E.; McCance, D. R.; Powell, L.; McMahon, R.; Trimble, E. R. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis, 2007, 194, e123-e130.
77. Ridker, P. M.; Rifai, N.; Pfeffer, M.; Sacks, F.; Lepage, S.; Braunwald, E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation, 2000, 101, 2149-53.
78. Koh, K. K.; Ahn, J. Y.; Jin, D. K.; Han, S. H.; Kim, H. S.; Choi, I. S.; Ahn, T. H.; Shin, E. K.; Jeong, E. M. Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. Int. J. Cardiol., 2004, 97, 239-44.
79. Deanfield, J. E.; Halcox, J. P.; Rabelink, T. J. Endothelial function and dysfunction: Testing and clinical relevance. Circulation, 2007, 115, 1285-95.
80. Hwang, S. J.; Ballantyne, C. M.; Sharrett, A. R.; Smith, L. C.; Davis, C. E.; Gotto, A. M., Jr.; Boerwinkle, E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study. Circulation, 1997, 96, 4219-25.
81. Luc, G.; Arveiler, D.; Evans, A.; Amouyel, P.; Ferrieres, J.; Bard, J. M.; Elkhalil, L.; Fruchart, J. C.; Ducimetiere, P. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: The PRIME Study. Atherosclerosis, 2003, 170, 169-76.
82. Ridker, P. M.; Hennekens, C. H.; Roitman-Johnson, B.; Stampfer, M. J.; Allen, J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet, 1998, 351, 88-92.
83. Blankenberg, S.; Rupprecht, H. J.; Bickel, C.; Peetz, D.; Hafner, G.; Tiret, L.; Meyer, J. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation, 2001, 104, 1336-42.
84. Jager, A.; van Hinsbergh, V. W.; Kostense, P. J.; Emeis, J. J.; Nijpels, G.; Dekker, J. M.; Heine, R. J.; Bouter, L. M.; Stehouwer, C. D. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: The Hoorn study. Diabetes, 2000, 49, 485-91.
85. Marchesi, S.; Lupattelli, G.; Lombardini, R.; Roscini, A. R.; Siepi, D.; Vaudo, G.; Pirro, M.; Sinzinger, H.; Schillaci, G.; Mannarino, E. Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia. J. Clin. Pharm. Ther., 2003, 28, 419-24.
86. Rosenson, R. S.; Wolff, D. A.; Huskin, A. L.; Helenowski, I. B.; Rademaker, A. W. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care, 2007, 30, 1945-51.
87. Kowalski, J.; Okopien, B.; Madej, A.; Zielinski, M.; Belowski, D.; Kalina, Z.; Herman, Z. S. Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia. Int. J. Clin. Pharmacol. Ther., 2003, 41, 241-7.
88. Empen, K.; Frost, R. J.; Geiss, H. C.; Otto, C.; Parhofer, K. G. Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule-1 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: A randomized cross-over trial. Cardiovasc. Diabetol., 2003, 2, 17.
89. Kovacs, I.; Toldy, E.; Abel, T.; Tarjan, J.; Csaszar, A. The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia. Endothelium, 2005, 12, 179-83.
90. Okapcova, J.; Gabor, D. The levels of soluble adhesion molecules in diabetic and nondiabetic patients with combined hyperlipoproteinemia and the effect of ciprofibrate therapy. Angiology, 2004, 55, 629-39.
91. Hernandez, C.; Lecube, A.; Barbera, G.; Chacon, P.; Lima, J.; Simo, R. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Med. Sci. Monit., 2003, 9, CR114-CR119.
92. Danesh, J.; Lewington, S.; Thompson, S. G.; Lowe, G. D.; Collins, R.; Kostis, J. B.; Wilson, A. C.; Folsom, A. R.; Wu, K.; Benderly, M.; Goldbourt, U.; Willeit, J.; Kiechl, S.; Yarnell, J. W.; Sweetnam, P. M.; Elwood, P. C.; Cushman, M.; Psaty, B. M.; Tracy, R. P.; Tybjaerg-Hansen, A.; Haverkate, F.; de Maat, M. P.; Fowkes, F. G.; Lee, A. J.; Smith, F. B.; Salomaa, V.; Harald, K.; Rasi, R.; Vahtera, E.; Jousilahti, P.; Pekkanen, J.; D'Agostino, R.; Kannel, W. B.; Wilson, P. W.; Tofler, G.; Arocha-Pinango, C. L.; Rodriguez-Larralde, A.; Nagy, E.; Mijares, M.; Espinosa, R.; Rodriquez-Roa, E.; Ryder, E.; Diez-Ewald, M. P.; Campos, G.; Fernandez, V.; Torres, E.; Marchioli, R.; Valagussa, F.; Rosengren, A.; Wilhelmsen, L.; Lappas, G.; Eriksson, H.; Cremer, P.; Nagel, D.; Curb, J. D.; Rodriguez, B.; Yano, K.; Salonen, J. T.; Nyyssonen, K.; Tuomainen, T. P.; Hedblad, B.; Lind, P.; Loewel, H.; Koenig, W.; Meade, T. W.; Cooper, J. A.; De Stavola, B.; Anti-Inflammatory Effects of Fibrates Current Medicinal Chemistry, 2009 Vol. 16, No. 6 683 Knottenbelt, C.; Miller, G. J.; Cooper, J. A.; Bauer, K. A.; Rosenberg, R. D.; Sato, S.; Kitamura, A.; Naito, Y.; Palosuo, T.; Ducimetiere, P.; Amouyel, P.; Arveiler, D.; Evans, A. E.; Ferrieres, J.; Juhan-Vague, I.; Bingham, A.; Schulte, H.; Assmann, G.; Cantin, B.; Lamarche, B.; Despres, J. P.; Dagenais, G. R.; Tunstall-Pedoe, H.; Woodward, M.; Ben Shlomo, Y.; Davey, S. G.; Palmieri, V.; Yeh, J. L.; Rudnicka, A.; Ridker, P.; Rodeghiero, F.; Tosetto, A.; et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA, 2005, 294, 1799-809.
93. Green, D.; Foiles, N.; Chan, C.; Schreiner, P. J.; Liu, K. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: The CARDIA Study. Atherosclerosis, 2008 Jul 2 [Epub ahead of print].
94. Kakafika, A. I.; Liberopoulos, E. N.; Mikhailidis, D. P. Fibrinogen: A predictor of vascular disease. Curr. Pharm. Des, 2007, 13, 1647-59.
95. Branchi, A.; Rovellini, A.; Sommariva, D.; Gugliandolo, A. G.; Fasoli, A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb. Haemost., 1993, 70, 241-3.
96. Ericsson, C. G.; Hamsten, A.; Nilsson, J.; Grip, L.; Svane, B.; de Faire, U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet, 1996, 347, 849-53.
97. Mathur, S.; Barradas, M. A.; Mikhailidis, D. P.; Dandona, P. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: A pilot study. Diabetes Res., 1990, 14, 133-8.
98. Papadakis, J. A.; Ganotakis, E. S.; Jagroop, I. A.; Winder, A. F.; Mikhailidis, D. P. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int. J. Cardiol., 1999, 69, 237-44.
99. Athyros, V. G.; Papageorgiou, A. A.; Athyrou, V. V.; Demitriadis, D. S.; Kontopoulos, A. G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care, 2002, 25, 1198-202.
100. Elisaf, M.; Tsimichodimos, V.; Bairaktari, E.; Siamopoulos, K. C. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J. Cardiovasc. Pharmacol., 1999, 34, 60-3.
101. Farnier, M.; Freeman, M. W.; Macdonell, G.; Perevozskaya, I.; Davies, M. J.; Mitchel, Y. B.; Gumbiner, B. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J., 2005, 26, 897-905.
102. Kontopoulos, A. G.; Athyros, V. G.; Papageorgiou, A. A.; Hatzikonstandinou, H. A.; Mayroudi, M. C.; Boudoulas, H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron. Artery Dis., 1996, 7, 843-50.
103. Mikhailidis, D. P.; Ganotakis, E. S.; Spyropoulos, K. A.; Jagroop, I. A.; Byrne, D. J.; Winder, A. F. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: Response to ciprofibrate or lifestyle advice. Int. Angiol., 1998, 17, 225-33.
104. Durrington, P. N.; Mackness, M. I.; Bhatnagar, D.; Julier, K.; Prais, H.; Arrol, S.; Morgan, J.; Wood, G. N. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis, 1998, 138, 217-25.
105. Kockx, M.; de Maat, M. P.; Knipscheer, H. C.; Kastelein, J. J.; Kluft, C.; Princen, H. M.; Kooistra, T. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients. Thromb. Haemost., 1997, 78, 1167-72.
106. Ohmori, R.; Momiyama, Y.; Taniguchi, H.; Takahashi, R.; Kusuhara, M.; Nakamura, H.; Ohsuzu, F. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis, 2003, 170, 333-7.
107. Minoretti, P.; Falcone, C.; Calcagnino, M.; Emanuele, E.; Buzzi, M. P.; Coen, E.; Geroldi, D. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur. Heart J., 2006, 27, 802-7.
108. Koenig, W.; Khuseyinova, N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 15-26.
109. de Lemos, J. A.; Morrow, D. A.; Sabatine, M. S.; Murphy, S. A.; Gibson, C. M.; Antman, E. M.; McCabe, C. H.; Cannon, C. P.; Braunwald, E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation, 2003, 107, 690-5.
110. Armstrong, E. J.; Morrow, D. A.; Sabatine, M. S. Inflammatory biomarkers in Mcute coronary syndromes: Part IV: matrix metalloproteinases and biomarkers of platelet activation. Circulation, 2006, 113, e382-e385.
111. Heeschen, C.; Dimmeler, S.; Hamm, C. W.; van den Brand, M. J.; Boersma, E.; Zeiher, A. M.; Simoons, M. L. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med., 2003, 348, 1104-11.
112. Garza, C. A.; Montori, V. M.; McConnell, J. P.; Somers, V. K.; Kullo, I. J.; Lopez-Jimenez, F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: A systematic review. Mayo Clin. Proc., 2007, 82, 159-65.
113. Tsimikas, S.; Tsironis, L. D.; Tselepis, A. D. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 2094-9.
114. Filippatos, T. D.; Gazi, I. F.; Liberopoulos, E. N.; Athyros, V. G.; Elisaf, M. S.; Tselepis, A. D.; Kiortsis, D. N. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis, 2007, 193, 428-37.
115. Kinlay, S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: A meta-analysis. J. Am. Coll. Cardiol., 2007, 49, 2003-9.
116. Muhlestein, J. B.; May, H. T.; Jensen, J. R.; Horne, B. D.; Lanman, R. B.; Lavasani, F.; Wolfert, R. L.; Pearson, R. R.; Yannicelli, H. D.; Anderson, J. L. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: The DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J. Am. Coll. Cardiol., 2006, 48, 396-401.
117. Athyros, V. G.; Mikhailidis, D. P.; Didangelos, T. P.; Giouleme, O. I.; Liberopoulos, E. N.; Karagiannis, A.; Kakafika, A. I.; Tziomalos, K.; Burroughs, A. K.; Elisaf, M. S. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: A randomised study. Curr. Med. Res. Opin., 2006, 22, 873-83.
118. Grundy, S. M.; Vega, G. L.; Yuan, Z.; Battisti, W. P.; Brady, W. E.; Palmisano, J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol., 2005, 95, 462-8.
119. Wierzbicki, A. S.; Mikhailidis, D. P.; Wray, R.; Schacter, M.; Cramb, R.; Simpson, W. G.; Byrne, C. B. Statin-fibrate combination: Therapy for hyperlipidemia: A review. Curr. Med. Res. Opin., 2003, 19, 155-68.
120. Tsiara, S.; Elisaf, M.; Mikhailidis, D. P. Early vascular benefits of statin therapy. Curr. Med. Res. Opin., 2003, 19, 540-56.
121. Tziomalos, K.; Athyros, V. G.; Mikhailidis, D. P. Statin discontinuation: An underestimated risk? Curr. Med. Res. Opin., 2008, 24, 3059-62.
122. Gazi, I. F.; Mikhailidis, D. P. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: An overview. Expert. Opin. Ther. Targets., 2006, 10, 851-66.
123. Kastelein, J. J.; Akdim, F.; Stroes, E. S.; Zwinderman, A. H.; Bots, M. L.; Stalenhoef, A. F.; Visseren, F. L.; Sijbrands, E. J.; Trip, M. D.; Stein, E. A.; Gaudet, D.; Duivenvoorden, R.; Veltri, E. P.; Marais, A. D.; de Groot, E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med., 2008, 358, 1431-43.
124. Mikhailidis, D. P.; Sibbring, G. C.; Ballantyne, C. M.; Davies, G. M.; Catapano, A. L. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr. Med. Res. Opin., 2007, 23, 2009-26.
125. Nakou, E. S.; Filippatos, T. D.; Georgoula, M.; Kiortsis, D. N.; Tselepis, A. D.; Mikhailidis, D. P.; Elisaf, M. S. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr. Med. Res. Opin., 2008, 24, 1919-29.
126. Davidson, M. H. The use of colesevelam hydrochloride in the treatment of dyslipidemia: A review. Expert. Opin. Pharmacother., 2007, 8, 2569-78.
127. Florentin, M.; Liberopoulos, E. N.; Mikhailidis, D. P.; Elisaf, M. S. Colesevelam hydrochloride in clinical practice: A new approach in the treatment of hypercholesterolaemia. Curr. Med. Res. Opin., 2008, 24, 995-1009.
128. Athyros, V. G.; Tziomalos, K.; Mikhailidis, D. P.; Pagourelias, E. D.; Kakafika, A. I.; Skaperdas, A.; Hatzitolios, A.; Karagiannis, A. Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? Expert. Opin. Pharmacother., 2007, 8, 2267-77.
129. Kuvin, J. T.; Dave, D. M.; Sliney, K. A.; Mooney, P.; Patel, A. R.; Kimmelstiel, C. D.; Karas, R. H. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am. J. Cardiol., 2006, 98, 743-5.
130. Balk, E. M.; Lichtenstein, A. H.; Chung, M.; Kupelnick, B.; Chew, P.; Lau, J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: A systematic review. Atherosclerosis, 2006, 189, 19-30.
131. Murphy, K. J.; Meyer, B. J.; Mori, T. A.; Burke, V.; Mansour, J.; Patch, C. S.; Tapsell, L. C.; Noakes, M.; Clifton, P. A.; Barden, A.; Puddey, I. B.; Beilin, L. J.; Howe, P. R. Impact of foods enriched with n-3 long-chain polyunsaturated fatty acids on erythrocyte n-3 levels and cardiovascular risk factors. Br. J. Nutr., 2007, 97, 749-57.
132. Tziomalos, K.; Athyros, V. G.; Mikhailidis, D. P. Fish oils and vascular disease prevention: An update. Curr. Med. Chem., 2007, 14, 2622-8.
133. Shen, J.; Arnett, D. K.; Parnell, L. D.; Peacock, J. M.; Lai, C. Q.; Hixson, J. E.; Tsai, M. Y.; Province, M. A.; Straka, R. J.; Ordovas, J. M. Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: The GOLDN study. Diabetes Care, 2008, 31, 910-5.
134. Tanne, D.; Benderly, M.; Goldbourt, U.; Boyko, V.; Brunner, D.; Graff, E.; Reicher-Reiss, H.; Shotan, A.; Mandelzweig, L.; Behar, S. A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study. Am. J. Med., 2001, 111, 457-63.